United States: The Warning Letter Is Only The Start

Last Updated: January 22 2014
Article by Ralph S. Tyler and Maggie Grace

So you've had a bad day — FDA has told you to stop marketing your product.  The good news, things can only get better, right?  Maybe not if a class action follows hot on the heels of FDA's order.  This, in brief, is the recent tale of woe of 23andMe.  See Casey v. 23andMe, Inc., No. 3:13-cv-02847 (S.D. Cal. Nov. 27, 2013).

The 23andMe example is only the most recent example of an FDA Warning Letter inspiring a class action.  See, e.g., Trujillo v. Avon Prods., Inc., No. CV12-09084 (C.D. Cal. filed Oct. 23, 2012) (class action filed less than three weeks after FDA Warning Letter); Nino v. L'Oreal USA, Inc., Lancôme, Inc., and Lancôme Luxury Prods., LLC, No. 1:12-cv-23462 (S.D. Fla. Sept. 21, 2012) (class action filed two weeks after FDA Warning Letter); Huey v. General Mills, Inc., No. 09-01368 (E.D. Cal. May 15, 2009) (class action filed less than two weeks after FDA Warning Letter); Mason v. The Coca-Cola Co., No. 1:09-cv-00220 (D.N.J. Jan. 14, 2009) (class action filed about a month after FDA Warning Letter).

As we wrote in a previous post, 23andMe manufactures and markets an at home genetic test which promises to provide information about potential health conditions and diseases.  On November 22, FDA issued a Warning Letter to the company ordering the company to stop marketing the product.  In FDA's view, the company had failed to substantiate that the test actually worked.  A class action lawsuit alleging unfair business practices, misrepresentation, and false advertising, among other claims, followed on November 27, only five days after the Warning Letter.

The allegations of the complaint make clear that "but for" the Warning Letter plaintiffs had no basis to initiate a lawsuit.  The Warning Letter is the sum and substance of the complaint, and plaintiffs make no attempt to suggest to the contrary.

The complaint does not allege, for example, that the sole named plaintiff, Ms. Lisa Casey of San Diego, or any unnamed class member actually received a false positive or a false negative 23andMe test result.  Similarly, the complaint does not allege that Ms. Casey or any class member received any unnecessary or inappropriate medical care or treatment as a result of relying on 23andMe test results.  Nor does the complaint allege that anyone failed to receive any necessary medical care or treatment in reliance on 23andMe test results.

The theory of plaintiffs' claims is that 23andMe made various promises about its product – for example, that it would provide information about a person's health and assist in planning for the future – and that the test "does none of those things and the results it provides are not supported by any scientific evidence." Complaint at ¶ 41.  The sole factual basis for these allegations about what the test won't do is FDA's Warning Letter.  Id. ¶¶ 15-21.

Basing a federal class action lawsuit on a Warning Letter raises at least two quite fundamental types of questions.  First, when a lawyer files a lawsuit on behalf of a party, his/her signature on the complaint is a certification "that to the best of the person's [lawyer's] knowledge, information, and belief, formed after an inquiry reasonable under the circumstances," the legal and factual claims have support.  Fed. R. Civ. P. 11(b) (emphasis added).  But here, there is no allegation of any inquiry beyond simply reasserting what is in FDA's Warning Letter.  Moreover, given that the lawsuit was filed a mere five days after issuance of the Warning Letter, there was little time for an "inquiry" beyond reading the Warning Letter.  Was there a "reasonable inquiry under the circumstances" when the target of the letter has yet to answer, as is its right, and when no independent third party has reviewed the conclusions of the letter and made any determination as to their validity?  Nestle was recently able to have a class action dismissed when the action was premised on little more than an FTC complaint and settlement.

Second, is merely buying a product that makes marketing claims which a government agency says are unproven "injury" sufficient to sustain federal jurisdiction, or does a plaintiff in a "follow-on" class action lawsuit have to demonstrate more?  The constitutional authority of the federal courts is limited to "cases and controversies," a limitation which has long been interpreted to require that a plaintiff have "standing" to bring a case.  "Standing," in turn, requires that the plaintiff has suffered or is at imminent risk of suffering "injury-in-fact."

One recent case suggests that it may not be sufficient in these types of cases to simply demonstrate that a company made false or misleading claims and that he or she purchased the product in reliance upon those claims and, thereby, suffered an economic loss.  In In re Cheerios Marketing & Sales Practices Litigation, No. 09-cv-2413, 2012 WL 3952069 (D.N.J. Sept. 10, 2012), six class action suits were filed shortly after an FDA Warning Letter regarding representations of the health benefits of Cheerios.  The district court held that the plaintiffs had not met the injury-in-fact requirement—and thus did not have standing to sue—because, for one, they continued to eat Cheerios after learning of the FDA letter.  The ruling suggests that in such a case, the plaintiff might have to show reliance upon the alleged misrepresentation and that he or she did not otherwise benefit by purchasing the product (e.g., eating Cheerios for their taste).

Of course 23andMe may have a more difficult time demonstrating a lack of reliance or that the plaintiff received some other benefit but as we discuss in more detail tomorrow, being served with a class action complaint increasingly does not mean that you are without the means to strike back.  In the meantime, however, the message of the 23andMe case and similar cases which have preceded it is clear: an FDA Warning Letter, and by implication similar governmental directives, may trigger private class action litigation.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions